Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

EBMT 2021 | Optimizing outcomes for patients with VOD/SOS

Paul Richardson • 14 Mar 2021

EBMT 2021

General Cyclosporine Defibrotide Fludarabine Gemtuzumab ozogamicin Inotuzumab ozogamicin Methotrexate Sirolimus Tacrolimus

Paul Richardson, MD, MSc, Dana-Farber Cancer Institute, Boston, MA, gives a presentation on the optimization of treatment for patients with veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS). Dr Richardson outlines risk stratification based on risk factors including biomarkers and treatment with gemtuzumab ozogamicin, sirolimus or tacrolimus. Dr Richardson also outlines the use of defibrotide in the treatment of VOD/SOS, giving an overview of its mechanism of action and summarizing data from clinical trials. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.

Novel therapeutic options and quadruplet regimens for newly diagnosed multiple myeloma

Paul Richardson • 29 Sep 2023

ANCHOR and LIGHTHOUSE trials: melflufen in multiple myeloma

Paul Richardson • 29 Sep 2023

Session highlights: managing the aging population in myeloma & promising treatment options

Paul Richardson • 29 Sep 2023

Exploring the potential role of melflufen in myeloma & updates from the LIGHTHOUSE trial

Paul Richardson • 12 May 2023

Related Videos

Hematological manifestations associated with primary immunodeficiency disorders

Thomas Fox • 15 Apr 2024

PHOEBUS trial: oral fecal microbiotherapy for increasing OS in patients undergoing alloSCT

Florent Malard • 11 Apr 2024

Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies

Florent Malard • 11 Apr 2024

PTCy as GvHD prophylaxis: side effects, optimizing the dose, and the effect of dose-reduction

Rémy Duléry • 15 Apr 2024